|Last Price$14.82||Day Change (%)-1.40%|
|Open Price$14.90||Day Change ($)-0.21|
|Day Range14.70–15.05||52-Week Range12.56–32.88|
As of Mon 12/29/2014 11:53 AM EST | USD
Theravance THRX reported second-quarter earnings that matched our expectations, and we are keeping our fair value estimate at $29 per share. The company continues to make progress in each of its programs, namely the addition of a second Phase IIb compound in the Beyond Advair trials and completion ...
Biotech companies' returns have diverged from the broader market in recent weeks amid concerns over greater regulation and price discounting.